Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daphnetin oral capsules to inhibit nasal epithelial ACE2 expression in healthy adults
ChiCTR2300077554Phase 4Recruiting
- Sponsor
- Wannan Medical College
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daphnetin in coronavirus disease 2019 (COVID-19), sponsored by Wannan Medical College. Primary endpoint: ACE2 expression in nasal mucosal epithelial cells. Started Nov 2023; status: recruiting.
02
Drugs
daphnetin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300077554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077554.